Microdosing GLP-1 usually means taking a dose below the standard labeled range, often a fraction of the lowest approved starting dose. People do it hoping to limit side effects or stretch a vial, but it is important to be clear that the approved doses come from large trials, and microdosing itself has not been studied in that way.
Reviewed for accuracy · Last reviewed July 8, 2026The dosing schedules for semaglutide and tirzepatide were set by clinical trials that titrated participants up to defined maintenance doses over several weeks. Microdosing is an informal practice of staying well below those studied doses, either indefinitely or as a slower on-ramp than the label describes.
The motivations people cite are usually reducing nausea and other gastrointestinal effects, which tend to be dose-related, or making a supply last longer. Those are understandable goals, but they describe a hope rather than a demonstrated result.
The weight and metabolic effects reported for these drugs were measured at the trial doses, not at fractions of them. A smaller dose may produce a smaller effect, no measurable effect, or a different balance of benefit and side effects, and there is no good trial data to say which. Treating a sub-therapeutic dose as if it delivers the headline results is not supported.
There is also a practical accuracy problem. Measuring a very small dose on an insulin syringe leaves more room for error, and reconstituting a vial to hit a tiny target dose reliably takes care. A calculator helps, but it does not remove the underlying uncertainty about whether the low dose does anything.